Y-mabs Therapeutics, INC

Y-mAbs Therapeutics, Inc. has completed its acquisition by Perseus BidCo US, Inc. and Yosemite Merger Sub, Inc. for approximately $413 million, leading to its delisting from Nasdaq.

Y-mAbs Therapeutics reports Q2 2025 financial results, exceeding revenue guidance, alongside a definitive agreement for SERB Pharmaceuticals to acquire the company for $412.0 million.

SERB Pharmaceuticals will acquire Y-mAbs Therapeutics, including its lead oncology asset DANYELZA, for $8.60 per share in an all-cash transaction valued at approximately $412 million.

Y-mAbs Therapeutics, Inc. announced the successful approval of all three proposals, including the election of a Class I director, ratification of its independent auditor, and advisory approval of executive compensation, at its annual meeting of stockholders held on July 11, 2025.

Y-mAbs Therapeutics, Inc. announced complete Part A data from its GD2-SADA Phase 1 Clinical Trial (Trial 1001), validating the safety and tolerability of its pretargeted radioimmunotherapy platform and outlining an expanded oncology pipeline.

Y-mAbs Therapeutics reports an 8% increase in DANYELZA net product revenue for Q1 2025, alongside advancements in their radiopharmaceutical programs.

Y-mAbs Therapeutics reported a narrowed net loss in Q2 2025, driven by reduced operating expenses, but saw a decline in DANYELZA product revenue, while announcing a definitive merger agreement at $8.60 per share.

Y-mAbs Therapeutics' Q1 2025 results show increased revenue driven by international DANYELZA sales, alongside ongoing clinical trials and a business realignment strategy.

Y-mAbs Therapeutics reports a net loss of $7 million for Q3 2024, with product revenue slightly down, while advancing its DANYELZA commercialization and SADA PRIT technology platform.

Y-mAbs Therapeutics reports a net loss of $9.2 million for Q2 2024, with product revenue increasing to $22.8 million.

Y-mAbs Therapeutics reports a net loss of $6.6 million for Q1 2024, with product revenue slightly decreasing, while prioritizing DANYELZA commercialization and SADA PRIT technology development.

Y-mAbs Therapeutics files an amendment to its 2024 Annual Report on Form 10-K to include Part III information and update the exhibit list, while also revising its non-employee director compensation policy.

Y-mAbs Therapeutics details its 2024 financial performance and strategic shift towards expanding DANYELZA's market presence and advancing its radiopharmaceutical platform.

Y-mAbs Therapeutics, Inc. details its financial status, strategic restructuring, and pipeline advancements in its annual 10-K filing, highlighting its focus on DANYELZA and SADA PRIT technology.

Y-mAbs Therapeutics Director Laura Hamill reported the disposition of common stock, restricted stock units, and stock options following the company's acquisition by Stark International Lux.

WG Biotech ApS reports the disposition of all its Y-mAbs Therapeutics shares following the company's merger into a private entity at $8.60 per share.

Y-mAbs Therapeutics SVP Douglas J. Gentilcore's stock options were converted to cash following the company's merger on September 16, 2025.

Director David N. Gill's Y-mAbs Therapeutics holdings were converted to cash following the company's acquisition by Stark International Lux.

Y-mAbs Therapeutics Director Ashu Tyagi reported the disposition of common stock and cancellation of restricted stock units and stock options following the company's acquisition.

Y-mAbs Therapeutics Chief Business Officer Thomas Gad disposed of all his common stock, RSUs, PRSUs, and stock options following the company's acquisition by Perseus BidCo US, Inc. for $8.60 per share.

Y-MABS Therapeutics, Inc. has filed its definitive proxy statement for its annual stockholder meeting on July 11, 2025, where shareholders will vote on the election of a Class I Director, the ratification of its independent auditor, and executive compensation.

Y-mAbs Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on July 11, 2025, to vote on director election, auditor ratification, and executive compensation.

Y-mAbs Therapeutics will hold its annual stockholder meeting on June 11, 2024, to elect directors, ratify the appointment of PricewaterhouseCoopers LLP, and approve executive compensation.

Y-mAbs Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 11, 2024, to vote on director elections, auditor ratification, and executive compensation.

Paradigm BioCapital Advisors and its affiliates have reported a complete divestment of their beneficial ownership in Y-mAbs Therapeutics, Inc. common stock.

Caligan Partners LP and David Johnson have reported a complete divestment of their beneficial ownership in Y-mAbs Therapeutics, Inc., now holding 0% of the common stock.

Beryl Capital Management and its affiliates have reported a complete divestment of their beneficial ownership in Y-mAbs Therapeutics, Inc., reducing their stake to 0%.

Glazer Capital, LLC and Paul J. Glazer have filed an amended Schedule 13G indicating they no longer beneficially own shares of Y-mAbs Therapeutics, Inc.

Acorn Bioventures and related entities, including Anders Hove, have disclosed a combined 6.2% beneficial ownership stake in Y-mAbs Therapeutics, Inc.

Glazer Capital and Paul J. Glazer have reported a beneficial ownership of 5.84% in Y-mAbs Therapeutics, Inc., totaling 2,654,700 shares of common stock.